Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$108.54NASDAQ Closing Price as of 4:00PM ET 9/16/19

Today's Change+1.14(1.06%)
Bid (Size)$107.07 (1)
Ask (Size)$109.30 (2)
Day Low / High$106.45 - 109.42
Volume2.1 M
 

View Biotechnology IndustryPeer Comparison as of 09/16/2019

 

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $108.54
Change: +1.14 (1.06%)
Volume: 2.1 M
4:00PM ET 9/16/2019
 
 

Agilent Technologies Inc ( NYSE )

Price: $77.15
Change: -0.75 (0.96%)
Volume: 2.9 M
6:30PM ET 9/16/2019
 
 

Incyte Corp ( NASDAQ )

Price: $78.34
Change: +1.91 (2.50%)
Volume: 1.1 M
4:00PM ET 9/16/2019
 
 

Exact Sciences Corp ( NASDAQ )

Price: $104.41
Change: -2.30 (2.16%)
Volume: 1.3 M
4:00PM ET 9/16/2019
 
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $285.89
Change: +4.27 (1.52%)
Volume: 476.1 K
4:00PM ET 9/16/2019
 

Read more news Recent News

Analyst Actions: BMO Capital Starts Alexion Pharmaceuticals at Outperform With $149 Price Target
7:25AM ET 9/12/2019 MT Newswires

Alexion Pharmaceuticals' (ALXN) average rating among analysts is a buy, with an average price target of $162. Price: 108.90, Change: -0.70, Percent Change:...

Forecast for Alexion Pharmaceuticals' Q3 Earnings Scaled Down
12:11AM ET 9/10/2019 MT Newswires

Alexion Pharmaceuticals Inc's September 30, 2019, forecasted quarterly earnings estimate (NASDAQ:ALXN, Recent Price: 106.40) has been lowered. This new...

Eidos Therapeutics Grants Alexion Pharmaceuticals Exclusive License to Develop AG10 in Japan
8:59AM ET 9/09/2019 MT Newswires

Alexion Pharmaceuticals (ALXN) and Eidos Therapeutics (EIDX), a subsidiary of BridgeBio Pharma (BBIO), said pre-market Monday they have entered into a deal...

Wedbush Shrugs Off Europe's Patent Ruling on Alexion Pharma's Solaris, Sees Barriers in Place - Stock Up 3%
3:39PM ET 9/06/2019 MT Newswires

Wedbush has reaffirmed its outperform rating on Alexion Pharmaceuticals (ALXN) with a price target of $155, after the European Patent Office declined to...

View all Commentary and Analysis

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival
10:14AM ET 9/13/2019 Zacks

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival
10:14AM ET 9/13/2019 Zacks

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

Viela Bio IPO: At Phase 3 Of Development With Positive Results
12:04PM ET 9/10/2019 Seeking Alpha

Apple, IPOs And German Auto (Stocks To Watch Podcast)
7:03AM ET 9/08/2019 Seeking Alpha

Company Profile

Business DescriptionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. View company web site for more details
Address121 Seaport Boulevard
Boston, Massachusetts 02210
Phone+1.475.230.2596
Number of Employees2,656
Recent SEC Filing09/05/20198-K
Chief Executive Officer & DirectorLudwig N. Hantson
Chief Financial Officer & Executive Vice PresidentPaul J. Clancy
Executive VP, Head-Research & DevelopmentJohn J. Orloff
Chief Compliance Officer & Executive VPIndrani M. Franchini

Company Highlights

Price Open$106.66
Previous Close$107.40
52 Week Range$92.56 - 141.86
Market Capitalization$24.3 B
Shares Outstanding224.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings18.14
Earnings per Share$7.31
Beta vs. S&P 500N/A
Revenue$4.1 B
Net Profit Margin29.84%
Return on Equity13.96%

Analyst Ratings as of 09/10/2019

Buy
13
Overweight
3
Hold
4
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset